In addition, the International Adjuvant Lung Cancer Trial (IALT) showed that those with ERCC1-positive tumors survived longer than those with ERCC1-negative tumors among patients who did not receive platinum-based chemotherapy (34). Here, ERCC1 is linked to lung cancer.